Sunshine Biopharma (SBFM) has released an update.
Sunshine Biopharma, Inc. teamed up with Aegis Capital Corp. for a public offering featuring over 71 million units, including common and pre-funded units with accompanying Series A and B warrants. This financial move, closing on February 15, 2024, generated a substantial $10 million, with plans for the capital to boost the company’s general funds and working capital. The offering included flexible options for investors, such as cashless warrant exercises and over-allotment provisions, aiming to adapt to future market conditions and shareholder approvals.
For further insights into SBFM stock, check out TipRanks’ Stock Analysis page.
